Open in interactive viewer → charts, metric popovers & call review

Merck's Third Raise Is Real — the 2027 Bridge Is Not

Guidance up again on Electronics and Bio-Techne, but Mavenclad is falling faster and Pergoveris is drifting
MRK.DE · Earnings Call · 2026-11-12

The headline is strength; the mix is the story

Kai Beckmann's first Q3 as group CEO delivered the third guidance raise of 2026: organic sales growth now 3-4%, EBITDA pre EUR 6.2-6.4bn, EPS pre EUR 8.30-8.70. Group organic growth accelerated to 5.1% from 4.1% in Q2, with foreign exchange turning from a headwind into a 1.5 percentage point tailwind. But EBITDA pre grew only 0.8%, because Q3 2025 carried a EUR 60m priority review voucher gain plus a EUR 59m benefit from South American legislative changes. The quality of the beat therefore sits in the divisions, not the group P&L. The strategic direction sketched in May is now being executed: four high-growth segments (biomanufacturing, discovery and development, semiconductor manufacturing, targeted specialty and rare disease), portfolio surgery (Bio-Techne in, CDMO out, Silence in), and footprint investment from Daejeon to Sheboygan. The keyword deck says it plainly — Bio Techne acquisition is the top company keyword this quarter, CDMO business second, leverage ratio third. The old narrative anchor, Process Solutions, has dropped out of the top ranks — not because the business is weak, but because the story has moved from operations to capital allocation.

Electronics is the upside surprise — and the biggest tape risk

Electronics organic growth accelerated to 13%, with Semiconductor Solutions up 19%. Ben Hein was explicit that “for the full year 2026, we expect this pricing effect to contribute roughly 2 percentage points to organic sales growth in Semiconductor Solutions” — Benjamin Hein, Executive · 2026-11-12 — a temporary raw-material pass-through, one-third in Q3 and two-thirds in Q4, expected to fade over 2027. The underlying driver is advanced-node capacity in logic and memory for AI. The raise to 10-11% organic from 6-9% is real, but it leans on a pricing tailwind management itself calls temporary, plus an eleventh consecutive quarter of year-over-year growth in semiconductor materials that is now well understood. Here is the tension: the global price tape has turned against the AI hardware complex. High bandwidth memory, data-center capacity, co-packaged optics and PCIe Gen 6 all sit on the 90-day and 30-day decliner lists — even as Merck raises Electronics guidance on AI demand. That does not make Merck wrong; its exposure is materials and metrology, not GPUs. But it means the market may not pay up for the raise until the AI capex tape stabilizes. Meanwhile Optronics remains a drag: consumer electronics demand is suppressed by high memory prices, and management expects a more pronounced Q4 decline there. Electronics is really two businesses — a cyclical-up advanced-nodes franchise and a weak consumer-facing optics franchise.

Life Science: Process Solutions is fine; the order trend is the question

Life Science organic growth was 6.1%, or 7.3% excluding tariff refunds to customers. Process Solutions grew 10.5% (12.6% underlying) with book-to-bill above 1 year-to-date. But Jean-Charles Wirth guided Q4 Process Solutions to mid-single-digit organic growth "due to a phasing effect" — a deliberate deceleration after a very strong nine months. The company keyword phasing effect captures it precisely. More important is what has quietly disappeared: in August Wirth warned that "if we have some inventory destocking effect, it may take place in 2027"; on this call he said lead times are back to normal (one to six months) and made no such warning. That is a soft positive the headline raise obscures. The bigger Life Science story is Bio-Techne. Helene von Roeder now expects it to add “close to 5% to group reported sales growth and about 10% to Life Science reported sales growth in 2027” — Helene von Roeder, CFO or Finance Executive · 2026-11-12, and 2026 guidance already includes one month of December contribution. The CDMO divestment to Lonza removes a sub-10%-of-Advanced-Solutions asset with below-sector margins; Silence Therapeutics adds Divesiran, a Phase III-ready siRNA in polycythemia vera. Leverage post-closing is now expected "clearly below" 3x net debt to EBITDA pre, better than the June projection. That is the strongest part of the quarter.

Healthcare: a steeper Mavenclad cliff and a slipping Pergoveris

Healthcare is the problem child. Rare Diseases contributed to organic growth for the first time, with Ogsiveo up 25% and Gomekli up 80%, and desmoid tumor is now a top-10 company keyword. But Specialty Care deteriorated: U.S. Mavenclad sales fell almost 50% sequentially in Q3, and guidance now assumes zero U.S. Mavenclad sales from November. Beckmann was blunt:

It's only fair to assume a rather steep Mavenclad decline in 2027.

Kai Beckmann, Group CEO · 2026-11-12
The Healthcare EBITDA pre margin is expected to decline from here, though management remains committed to north of 30%. The second disappointment is Pergoveris. In November 2025 Danny Bar-Zohar said the company was “working towards a launch of Pergoveris in the U.S. in the second half of 2026 under the Commissioner's National Priority Review Voucher Program” — Danny Bar-Zohar, Executive · 2025-11-13. On this call: “we are still under review. We are collaborating with the FDA, and we are expecting a decision in the coming months.” — Danny Bar-Zohar, Executive · 2026-11-12 The CNPV has not expired and the file was accepted, but the H2 2026 U.S. launch is now at risk — and Pergoveris is the growth engine of the Fertility franchise. Management also formally walked away from its Lp(a) asset after the Novartis pelacarsen HORIZON readout, a rare public admission of pipeline pruning.

What matters from here

Merck is not broken; it is a company in transition, and the transition is being executed at pace. The third raise is real, Electronics and Life Science are both growing above their midterm trajectories, and the portfolio moves are strategically coherent — out of low-margin CDMO, into Bio-Techne's tools and Silence's siRNA, with a stronger balance sheet than expected. But the 2027 setup is less comfortable than the 2026 headline, and management's own language has cooled. In August Beckmann said “2027 should be well in line with our projections from last year's CMD.” — Kai Beckmann, Group CEO · 2026-08-06 This time he added the qualifiers: tough Process Solutions comps in H1, a steep Mavenclad decline, and a Q4 slowdown that "we expect to continue into early next year." Bio-Techne's reported contribution will mask some of that, but it does not fix the organic base. The company's keyword profile has migrated from order trend and Process Solutions toward deal-making and leverage — which means the next leg depends on closing and integrating acquisitions rather than on the base business accelerating. For a company of this scale, that is a lot of execution risk to underwrite without a confirming price move. The third raise buys time; the 2027 organic bridge is the real test.